Andersson Martin, Johansson Lennart, Minarik David, Leide-Svegborn Sigrid, Mattsson Sören
Medical Radiation Physics, Department of Clinical Sciences Malmö, Skåne University Hospital, Lund University, Malmö, Sweden.
Department of Radiation Sciences, Umeå University, Umeå, Sweden.
EJNMMI Phys. 2014 Dec;1(1):9. doi: 10.1186/2197-7364-1-9. Epub 2014 Sep 29.
Effective dose represents the potential risk to a population of stochastic effects of ionizing radiation (mainly lethal cancer). In recent years, there have been a number of revisions and updates influencing the way to estimate the effective dose. The aim of this work was to recalculate the effective dose values for the 338 different radiopharmaceuticals previously published by the International Commission on Radiological Protection (ICRP).
The new estimations are based on information on the cumulated activities per unit administered activity in various organs and tissues and for the various radiopharmaceuticals obtained from the ICRP publications 53, 80 and 106. The effective dose for adults was calculated using the new ICRP/International Commission on Radiation Units (ICRU) reference voxel phantoms and decay data from the ICRP publication 107. The ICRP human alimentary tract model has also been applied at the recalculations. The effective dose was calculated using the new tissue weighting factors from ICRP publications 103 and the prior factors from ICRP publication 60. The results of the new calculations were compared with the effective dose values published by the ICRP, which were generated with the Medical Internal Radiation Dose (MIRD) adult phantom and the tissue weighting factors from ICRP publication 60.
For 79% of the radiopharmaceuticals, the new calculations gave a lower effective dose per unit administered activity than earlier estimated. As a mean for all radiopharmaceuticals, the effective dose was 25% lower. The use of the new adult computational voxel phantoms has a larger impact on the change of effective doses than the change to new tissue weighting factors.
The use of the new computational voxel phantoms and the new weighting factors has generated new effective dose estimations. These are supposed to result in more realistic estimations of the radiation risk to a population undergoing nuclear medicine investigations than hitherto available values.
有效剂量代表了电离辐射(主要是致死性癌症)对人群产生随机效应的潜在风险。近年来,有多项修订和更新影响了有效剂量的估算方法。本研究的目的是重新计算国际放射防护委员会(ICRP)先前公布的338种不同放射性药物的有效剂量值。
新的估算基于从ICRP第53、80和106号出版物中获得的各种放射性药物在不同器官和组织中每单位给药活度的累积活度信息。使用新的ICRP/国际辐射单位委员会(ICRU)参考体素模型和ICRP第107号出版物中的衰变数据计算成人的有效剂量。ICRP人体消化道模型也应用于重新计算中。使用ICRP第103号出版物中的新组织权重因子和ICRP第60号出版物中的先前因子计算有效剂量。将新计算结果与ICRP公布的有效剂量值进行比较,后者是使用医学内照射剂量(MIRD)成人模型和ICRP第60号出版物中的组织权重因子生成的。
对于79%的放射性药物,新计算得出的每单位给药活度有效剂量低于先前估计值。所有放射性药物的平均有效剂量降低了25%。与采用新的组织权重因子相比,使用新的成人计算体素模型对有效剂量变化的影响更大。
使用新的计算体素模型和新的权重因子产生了新的有效剂量估算值。与目前可用的值相比,这些估算值应该能更真实地评估接受核医学检查的人群所面临的辐射风险。